Egilmez NK - Search Results

1

Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma.

Hess SD, Egilmez NK, Bailey N, Anderson TM, Mathiowitz E, Bernstein SH, Bankert RB. Hess SD, et al. Among authors: egilmez nk. J Immunol. 2003 Jan 1;170(1):400-12. doi: 10.4049/jimmunol.170.1.400. J Immunol. 2003. PMID: 12496425

2

Human CD4+ effector T cells mediate indirect interleukin-12- and interferon-gamma-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice.

Egilmez NK, Hess SD, Chen FA, Takita H, Conway TF, Bankert RB. Egilmez NK, et al. Cancer Res. 2002 May 1;62(9):2611-7. Cancer Res. 2002. PMID: 11980657

3

Cytokines delivered by biodegradable microspheres promote effective suppression of human tumors by human peripheral blood lymphocytes in the SCID-Winn model.

Egilmez NK, Jong YS, Hess SD, Jacob JS, Mathiowitz E, Bankert RB. Egilmez NK, et al. J Immunother. 2000 Mar-Apr;23(2):190-5. doi: 10.1097/00002371-200003000-00003. J Immunother. 2000. PMID: 10746545

4

Human inflammatory cells within the tumor microenvironment of lung tumor xenografts mediate tumor growth suppression in situ that depends on and is augmented by interleukin-12.

Sugiyama Y, Kato M, Chen FA, Williams SS, Kawaguchi Y, Miya K, Jong YS, Mathiowitz E, Egilmez NK, Bankert RB. Sugiyama Y, et al. Among authors: egilmez nk. J Immunother. 2001 Jan-Feb;24(1):37-45. doi: 10.1097/00002371-200101000-00005. J Immunother. 2001. PMID: 11211147

5

Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.

Hess SD, Egilmez NK, Shiroko J, Bankert RB. Hess SD, et al. Among authors: egilmez nk. Cancer Gene Ther. 2001 May;8(5):371-7. doi: 10.1038/sj.cgt.7700314. Cancer Gene Ther. 2001. PMID: 11477457

6

Comparison of human lung cancer/SCID mouse tumor xenografts and cell culture growth with patient clinical outcomes.

Anderson TM, Hess SD, Egilmez NK, Nwogu CE, Lenox JM, Bankert RB. Anderson TM, et al. Among authors: egilmez nk. J Cancer Res Clin Oncol. 2003 Oct;129(10):565-8. doi: 10.1007/s00432-003-0473-3. Epub 2003 Aug 16. J Cancer Res Clin Oncol. 2003. PMID: 12923636

7

Patient immune response to tumors monitored using SCID mouse models.

Bankert RB, Chen FA, Sugiyama Y, Egilmez N. Bankert RB, et al. Immunol Invest. 2000 May;29(2):171-6. doi: 10.3109/08820130009062301. Immunol Invest. 2000. PMID: 10854186 Review. No abstract available.

8

SCID mouse models to study human cancer pathogenesis and approaches to therapy: potential, limitations, and future directions.

Bankert RB, Hess SD, Egilmez NK. Bankert RB, et al. Among authors: egilmez nk. Front Biosci. 2002 Apr 1;7:c44-62. doi: 10.2741/A758. Front Biosci. 2002. PMID: 11915860 Review.

9

Tumor vaccination with cytokine-encapsulated microspheres.

Egilmez NK, Jong YS, Mathiowitz E, Bankert RB. Egilmez NK, et al. Methods Mol Med. 2003;75:687-96. doi: 10.1385/1-59259-324-0:687. Methods Mol Med. 2003. PMID: 12407772 No abstract available.

10

Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.

Hill HC, Conway TF Jr, Sabel MS, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK. Hill HC, et al. Among authors: egilmez nk. Cancer Res. 2002 Dec 15;62(24):7254-63. Cancer Res. 2002. PMID: 12499267

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

105 results

Search Page

Filters